MedTrace Logo

Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients

NCT05424315 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-11-19

No results posted yet for this study

Summary

Sodium glucose co-transporter 2 inhibitors (SGLT2i) proved their favorable outcomes in heart failure. However, it is still unknown if their role extent into preventing heart failure, especially after acute myocardial infarction. This study aimed at identifying if there is such role for SGLT2i.

Conditions

  • Anterior MI

Interventions

DRUG

Dapagliflozin 10mg

10mg Tab once daily

DRUG

Glucose Tab

Placebo Oral Tablet

Sponsors & Collaborators

  • Ain Shams University

    collaborator OTHER

  • Omar Younis

    lead OTHER_GOV

Principal Investigators

  • Khairy Abdul-Dayem, M.D. · Cardiology Department, Faculty of Medicine, Ain Shams University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-01
Primary Completion
2022-04-30
Completion
2022-04-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05424315 on ClinicalTrials.gov